Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells

@article{Grabinski2014IbrutinibP,
  title={Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells},
  author={Nicole Grabinski and Florian Ewald},
  journal={Investigational New Drugs},
  year={2014},
  volume={32},
  pages={1096-1104}
}
Ibrutinib (formerly PCI-32765) is a specific, irreversible, and potent inhibitor of Burton’s tyrosine kinase (BTK) developed for the treatment of several forms of blood cancer. It is now an FDA-approved drug marketed under the name ImbruvicaTM (Pharmacyclics, Inc.) and successfully used as an orally administered second-line drug in the treatment of mantle cell lymphoma. Since BTK is predominantly expressed in hematopoietic cells, the sensitivity of solid tumor cells to Ibrutinib has not been… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS